Physician profile
George P Therapondos
NPI 1093099715
$364,507.25
in general payments reported to CMS, 2019-2025
18 companies · $133K in 2025
The $133K reported for 2025 was more than what 95% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,885 · 2021: $33K · 2022: $21K · 2023: $77K · 2024: $68K · 2025: $133K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Consulting Fee: $80K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Travel and Lodging: $24K · Food and Beverage: $7,312 · Honoraria: $4,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,794.63 |
| Consulting Fee | $80,308.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,620.00 |
| Travel and Lodging | $23,691.59 |
| Food and Beverage | $7,311.84 |
| Honoraria | $4,960.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107,391.37 | 2021-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $95,776.47 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $46,540.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Mallinckrodt Hospital Products INC. | $35,841.85 | 2022-2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $35,569.06 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $20,285.28 | 2019-2025 | Livdelzi, Epclusa |
| Boston Scientific Corporation | $8,582.97 | 2019-2021 | |
| Janssen Biotech, INC. | $4,753.60 | 2019 | |
| Biomarin Pharmaceutical INC. | $3,800.00 | 2021 | |
| Eisai INC. | $3,309.70 | 2019 | |
| Astrazeneca Uk Limited | $1,611.00 | 2023 | |
| Celgene Corporation | $877.95 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $88.69 | 2021 | |
| Dova Pharmaceuticals | $50.89 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $27.92 | 2024 | Utaswako Afp-L3 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Therapondos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.